Keyphrases
Adipogenesis
12%
Adipose Tissue
25%
Beneficial Effects
12%
Clinical Trials
25%
Co-agonist
12%
Dual Agonist
12%
Expression Level
25%
Health Burden
12%
Hepatic Expression
12%
High-level Expression
12%
Liver
12%
Liver-specific
12%
New Treatment Options
25%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Nonalcoholic Steatohepatitis
25%
Nuclear Receptors/peroxisome Proliferator-activated Receptor
12%
Peroxisome Proliferator-activated Receptor
100%
Peroxisome Proliferator-activated Receptor Agonists
12%
Preclinical Research
12%
Primary Function
12%
Specific Action
12%
Thiazolidinediones
12%
Treatment Options
12%
Unwanted Effects
12%
Weight Gain
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cell Nucleus Receptor
11%
Clinical Research
11%
Clinical Trial
22%
Nonalcoholic Fatty Liver
100%
Peroxisome Proliferator Activated Receptor
100%
Peroxisome Proliferator Activated Receptor Gamma
100%
PPAR Agonist
11%
Prevalence
11%
Thiazolidinedione
11%